<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome (AS)</z:e> is a severe <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological disorder</z:e> characterized by <z:hpo ids='HP_0001249'>mental retardation</z:hpo>, motor dysfunction and <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We show that the molecular and cellular deficits of an AS mouse model can be rescued by introducing an additional mutation at the inhibitory phosphorylation site of alphaCaMKII </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, these double mutants no longer show the behavioral deficits seen in AS mice, suggesting that these deficits are the direct result of increased inhibitory phosphorylation of alphaCaMKII </plain></SENT>
</text></document>